An Early Phase 1 interventional study of Vaccine in Dengue, sponsored by Prince of Songkla University. Completed at 2 sites in Thailand. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Prince of Songkla University · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Dengue with a site in Thailand — 6 open to participants now, 8 under way, 4 of them phase 3. Dengue · Thailand.
Among the 30 studies in Dengue with a site in Thailand, this one is the 17th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2025, is one of 2 in phase 1, and was the 25th registered.
283 studies on the registry are indexed under Dengue; 44 are open to participants now.
Browse Dengue studies →6 of the 30 studies in Dengue with a site in Thailand are open now. Recruiting first, the newest first:
Mahidol University · Sites in Thailand
Takeda · Sites in Thailand, Colombia
Ages 6 mo–20 mo · Healthy volunteers
Takeda · Sites in Thailand, Indonesia, Malaysia
Ages 6–12 · Healthy volunteers
Phramongkutklao College of Medicine and Hospital · Sites in Thailand
Ages 20+
Oxford University Clinical Research Unit, Vietnam · Sites in Thailand, Bangladesh, Brazil and 7 more countries
Ages 5+
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 8
First in 2001; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 132 across 197 interventional studies indexed under Dengue.
Median enrollment 147 across the 23 interventional studies, 1,000 across the 7 observational. Of the 21 that completed or were terminated, 11 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 30 have an industry lead sponsor. The 10 most frequent:
Prince of Songkla University is the lead sponsor of 116 studies on the registry; 13 are open to participants now.
Prince of Songkla University has 1 study filed under Dengue — fewer than ten, so there is no comparison to draw.
3 of the studies in Dengue with a site in Thailand that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747130Phase 3Phramongkutklao College of Medicine and HospitalEfficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients | 2027-01 |
| NCT06579755Phase 3TakedaA Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) | 2027-04-14 |
| NCT07759596Mahidol UniversityBridging Economics and Public Trust: A Study of Dengue Vaccine Cost-effectiveness and Acceptance in Thais Visiting Hospital | 2026-12-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Dengue with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Official title: Immunogenicity of an intradermal Qdenga vaccine among healthy volunteers: A pilot study
As in the setting of low- to middle-income countries, to demonstrating that lower doses of vaccine via intradermal route can still elicit robust immune responses, thereby lowering the overall cost of vaccination might be particularly meaningful ,with possible extra benefit of experiencing fewer side effects or risk of allergy. This study goal is to explores the potential of intradermal administration of Qdenga, hypothesizing that a lower dose via this route could achieve adequate immunogenicity compared to the standard subcutaneous administration, thus offering a cost-effective alternative particularly in low-resource settings where dengue is most prevalent.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subcutaneous Qdenga for 1st vaccination then intradermal Qdenga for 2nd vaccination
Biological: Vaccine
subcutaneous Qdenga for 1st vaccination then subcutaneous Qdenga for 2nd vaccination
Biological: Vaccine
Subcutaneous route vs Intradermal route
Dengue IgG Level
To measure Antibody level for dengue by ELISA on day 0, day 30 and day 120 after 1st vaccination
Time frame: Day 0 (Baseline), Day 30 (30 days post 1st vaccination) and Day 120 (30 days post 2nd vaccination)
CD4 T Cell Responses
To measure T cell responses to dengue antigen by ELISpot on day 0, day 30 and day 120 after 1st vaccination.
Time frame: Day 0 (Baseline), Day 30 (30 days post 1st vaccination) and Day 120 (30 days post 2nd vaccination)
CD8 T Cell Response
To measure T cell responses to dengue antigen by ELISpot on day 0, day 30 and day 120 after 1st vaccination.
Time frame: Day 0 (Baseline), Day 30 (30 days post 1st vaccination) and Day 120 (30 days post 2nd vaccination)
All-Cause Mortality
Death from any cause occurring from the first vaccination until the end of the 120-day follow-up period.
Time frame: at day 7 and 30 post each vaccination
Serious Adverse Events
Any untoward medical occurrence during the study period that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect, regardless of its relationship to the study vaccine.
Time frame: at day 7 and 30 post each vaccination
Local Reactions
\- Include any reported pain, swelling, erythema or nodule at the vaccination site
Time frame: at day 7 and 30 post each vaccination
Systemic Reactions
fever, chill, fatique, headache, myalgia
Time frame: at day 7 and 30 post each vaccination
Pain at Vaccination Site, 7 Day Post 1st Vaccination
Injection-site pain reported during the 7-day period following the first vaccine dose.
Time frame: 7 day post 1st vaccination
Erythema at Vaccination Site, 7 Day Post 1st Vaccination
Erythema at vaccination site reported during the 7-day period following the first vaccine dose.
Time frame: 7 day post 1st vaccination
Malaise, 7 Day Post 1st Vaccination
Self-reported malaise during the 7-day period following the first vaccine dose.
Time frame: 7 day post 1st vaccination
Headache, 7 Day Post 1st Vaccination
Self-reported headache during the 7-day period following the first vaccine dose.
Time frame: 7 day post 1st vaccination
Erythema at Vaccination Site, 7 Day Post 2nd Vaccination
Erythema at vaccination site reported during the 7-day period following the second vaccine dose.
Time frame: 7 day post 2nd vaccination
Twenty-nine adult volunteers were assessed for eligibility. Twenty-four eligible participants were randomized in a 1:1 ratio to the SC-SC or SC-ID group (12 participants per group).
| Milestone | SC ID | SC SC |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
To measure Antibody level for dengue by ELISA on day 0, day 30 and day 120 after 1st vaccination
| RU/ml | SC ID | SC SC |
|---|---|---|
| Baseline | 108.9 (102.2 to 124.8) | 104.0 (104.0 to 113.0) |
| Day 30 | 158.5 (151.1 to 164.5) | 143.2 (129.2 to 150.1) |
| Day 120 | 148.6 (143.3 to 159.4) | 141.3 (127.1 to 152.8) |
To measure T cell responses to dengue antigen by ELISpot on day 0, day 30 and day 120 after 1st vaccination.
| SFCs per 10^6 PBMCs | SC ID | SC SC |
|---|---|---|
| Baseline | 22.0 (17.8 to 81.3) | 15.0 (5.0 to 38.0) |
| Day 30 | 137.5 (60.8 to 178.3) | 103.0 (46.0 to 134.0) |
| Day 120 | 98.5 (21.0 to 163.8) | 94.5 (67.3 to 127.0) |
To measure T cell responses to dengue antigen by ELISpot on day 0, day 30 and day 120 after 1st vaccination.
| SFCs per 10^6 PBMCs | SC ID | SC SC |
|---|---|---|
| Baseline | 5.0 (1.8 to 38.5) | 11.0 (1.0 to 47.0) |
| Day 30 | 62.0 (24.5 to 105.5) | 11.0 (2.5 to 67.0) |
| Day 120 | 6.0 (0.0 to 17.0) | 10.0 (2.5 to 49.5) |
Death from any cause occurring from the first vaccination until the end of the 120-day follow-up period.
| Participants | SC ID | SC SC |
|---|---|---|
| All-Cause mortality | 0 | 0 |
Any untoward medical occurrence during the study period that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect, regardless of its relationship to the study vaccine.
| Participants | SC ID | SC SC |
|---|---|---|
| Serious Adverse Events | 0 | 0 |
\- Include any reported pain, swelling, erythema or nodule at the vaccination site
| Participants | SC ID | SC SC |
|---|---|---|
| Local Reactions | 3 | 1 |
fever, chill, fatique, headache, myalgia
| Participants | SC ID | SC SC |
|---|---|---|
| Systemic Reactions | 0 | 2 |
Injection-site pain reported during the 7-day period following the first vaccine dose.
| Participants | SC ID | SC SC |
|---|---|---|
| Pain at Vaccination Site, 7 Day Post 1st Vaccination | 2 | 1 |
Erythema at vaccination site reported during the 7-day period following the first vaccine dose.
| Participants | SC ID | SC SC |
|---|---|---|
| Erythema at Vaccination Site, 7 Day Post 1st Vaccination | 2 | 0 |
Self-reported malaise during the 7-day period following the first vaccine dose.
| Participants | SC ID | SC SC |
|---|---|---|
| Malaise, 7 Day Post 1st Vaccination | 0 | 1 |
Self-reported headache during the 7-day period following the first vaccine dose.
| Participants | SC ID | SC SC |
|---|---|---|
| Headache, 7 Day Post 1st Vaccination | 0 | 1 |
Erythema at vaccination site reported during the 7-day period following the second vaccine dose.
| Participants | SC ID | SC SC |
|---|---|---|
| Erythema at Vaccination Site, 7 Day Post 2nd Vaccination | 2 | 0 |
Collected over Day 37, 60 (7 and 30 days post 1st vaccination) and Day 97, 120 (7 and 30 days post 2nd vaccination). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SC ID | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| SC SC | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Event | SC ID | SC SC |
|---|---|---|
| Local reactionsSkin and subcutaneous tissue disorders | 3/12 | 1/12 |
| Systemic reactionsImmune system disorders | 0/12 | 2/12 |
| Pain at vaccination site, 7 day post 1st vaccinationSkin and subcutaneous tissue disorders | 2/12 | 1/12 |
| Erythema at vaccination site, 7 day post 1st vaccinationSkin and subcutaneous tissue disorders | 2/12 | 0/12 |
| Erythema at vaccination site, 7 day post 2nd vaccinationSkin and subcutaneous tissue disorders | 2/12 | 0/12 |
| Malaise, 7 day post 1st vaccinationGeneral disorders | 0/12 | 1/12 |
| Headache, 7 day post 1st vaccinationNervous system disorders | 0/12 | 1/12 |
| Age, Continuous(year) | SC ID | SC SC | Total |
|---|---|---|---|
| Median | 32.2 (23.9 to 40.5) | 39 (32 to 46) | 35.6 (27.3 to 43.9) |
| Sex: Female, Male(Participants) | SC ID | SC SC | Total |
|---|---|---|---|
| Female | 10 | 11 | 21 |
| Male | 2 | 1 | 3 |
| Body Mass Index(kg/m^2) | SC ID | SC SC | Total |
|---|---|---|---|
| Median | 21.18 (19.87 to 24.97) | 20.96 (20.34 to 23.34) | 21.05 (20.00 to 24.81) |
| Race and Ethnicity Not Collected(Participants) | SC ID | SC SC | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — The data will be anonymized.
Ran from Apr 2025 to primary completion in Aug 2025, 4 months.
Results were first posted in Jan 2026, 4 months after primary completion.
Of 22 phase 1 interventional studies under Dengue, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prince of Songkla University →